Virtus Fund Advisers’s Ligand Pharmaceuticals LGND Stock Holding History

Virtus Fund Advisers’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$981K	Buy	+11,479	New	+$995K	0.01%	291
2017 Q1	–	Sell	-8,409	Closed	-$533K	–	540
2016 Q4	$533K	Hold	8,409	–	–	﹤0.01%	327
2016 Q3	$535K	Sell	8,409 -2,041	-20%	-$150K	﹤0.01%	321
2016 Q2	$796K	Sell	10,450 -3,826	-27%	-$284K	0.01%	288
2016 Q1	$954K	Sell	14,276 -3,083	-18%	-$187K	0.01%	284
2015 Q4	$1.17M	Sell	17,359 -181	-1%	-$11.2K	0.01%	275
2015 Q3	$937K	Sell	17,540 -26,038	-60%	-$1.58M	0.01%	284
2015 Q2	$2.74M	Sell	43,578 -607	-1%	-$33.1K	0.02%	282
2015 Q1	$2.13M	Sell	44,185 -11,901	-21%	-$456K	0.02%	315
2014 Q4	$1.86M	Buy	56,086 +25,647	+84%	+$834K	0.01%	338
2014 Q3	$892K	Sell	30,439 -2,621	-8%	-$87K	0.01%	401
2014 Q2	$1.28M	Buy	+33,060	New	+$1.34M	0.01%	415

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Virtus Fund Advisers's LGND Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Ligand Pharmaceuticals (LGND) in Q4 2017: 11,479 shares worth $981K. The stake represents 0.01% of the portfolio and ranks #291 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in LGND as recently as Q4 2016.

Virtus Fund Advisers first reported a position in LGND in Q2 2014 and has held it in 12 quarters since. The position peaked at $2.74M in Q2 2015. 298 funds tracked by Wall St. Rank hold LGND as of Q4 2017.

Virtus Fund Advisers held 11,479 shares of Ligand Pharmaceuticals worth $981K as of Q4 2017.
Ligand Pharmaceuticals was a new Virtus Fund Advisers position in Q4 2017.
Ligand Pharmaceuticals made up 0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #291 holding.
Virtus Fund Advisers first reported a position in Ligand Pharmaceuticals in Q2 2014 and has held it in 12 quarters since.
Virtus Fund Advisers's Ligand Pharmaceuticals position peaked at $2.74M in Q2 2015.
298 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.